TARGET-EU: Dapagliflozin and major adverse cardiovascular events in type 2 diabetes

29/05/2026
29/05/2026
EU PAS number:
EUPAS1000000979
Study
Planned
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Emulation_Protocol_CS3_REV5_clean.pdf

English (800.19 KB - PDF) View document
Study results
Study report
Other information
Study, other information

CS3_Feasibility Assessment.pdf

English (458.99 KB - PDF) View document